| 2006D-0383 | Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases | |||||||||||||||||||||||
| FDA Comment Number : | EC2860 | |||||||||||||||||||||||
| Submitter : | Mr. Paul Moses | Date & Time: | 12/11/2006 10:12:54 | |||||||||||||||||||||
| Organization : | Mr. Paul Moses | |||||||||||||||||||||||
| Category : | Individual Consumer | |||||||||||||||||||||||
| Issue Areas/Comments | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| Reference Docket Number 2006D0383
Hi Folks - There are a number of cell lines which have originated from ethical and completely non-controversial sources for the development of vaccines. I support an FDA recommendation that pharmaceutical companies use these cells from non-controversial sources instead of cells derived from aborted children. Vaccines can and are being manufactured from non-controversial sources. Thank you for you kind consideration. | ||||||||||||||||||||||||